Purchase this article with an account.
Mathias M. Maier, Thomas Groneberg, Nikolaus Feucht, Carsten H. Meyer, Georg Spital, Joachim Wachtlin, Lars O. Hattenbach, Nicolas Feltgen, Chris P. Lohmann; Dexamethasone Intravitreal Implant (Ozurdex®) In Patients With Macular Edema Due To Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):920.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To asses the therapeutic effect of the dexamethasone implant (Ozurdex®) on macular edema in relation to duration in patients with retinal vein occlusion (RVO).
In a clinical, non randomized, multicenter retrospective study 135 patients with vision loss owing to macular edema associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) were included.BCVA and CRT (measured by SD-OCT) at baseline and 3 months after injection of the dexamethasone implant (Ozurdex®) in patients suffering from macular edema after fresh RVO (0-12 weeks, n=35), intermediate RVO (13-39 weeks, n=51) and longstanding RVO (> 40 weeks, n=49) were compared.
There was no difference in BCVA at baseline between the groups (BCVA logMAR was 0,73 for fresh; 0,68 for intermediate and 0,81 for the longstanding group). There was significant and similar increase of BCVA for all groups (BCVA logMAR: fresh 0,18 p=0,004; intermediate 0,15 p=0,004; longstanding 0,21 p=0,000). We found a significant reduction in CRT for all groups. Reduction in CRT was more pronounced in patients with fresh and intermediate RVO (p=0,006, p=0,002), but CRT at baseline was significant less in longstanding RVO in comparison to fresh and intermediate RVO (p=0,015; p=0,010).
In our study increase of BCVA seems to be independent of duration of RVO. A significant reduction in CRT was also found in patients with longstanding RVO.
This PDF is available to Subscribers Only